Nemvaleukin alfa

Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer.

Nemvaleukin alfa activates lymphocyte subsets from cynomolgus monkey and human samples, with EC₅₀s of 0.45-2.2 nM^[2].
Nemvaleukin alfa (0-100 nM, 30 min) induces the activation of intermediate-affinity IL-2R on human cells (HH cells)^[3].
Nemvaleukin alfa (0-100 nM, 30 min) induces pSTAT5 in NK cells with an EC₅₀ of 0.45 nM^[3].
Nemvaleukin alfa (0.5 nM, 5 days) induces the activation of effector lymphocytes isolated from human peripheral blood^[3].

Nemvaleukin alfa (6 mg/kg, s.c., every 4 days) inhibits SCLC tumor growth in mice^[1].

References:
[1]. Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.
[2]. Lopes JE, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2021 Nov;379(2):203-210.
[3]. Lopes JE, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.